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Rationale: Patients with COPD and hypercapnic respiratory failure have a worse prognosis and
experience a faster deterioration in their pulmonary function. The benefit of home NPPV
following an acute exacerbation of COPD with hypercapnic respiratory failure is not well un-
derstood.
Objectives: To evaluate the effect of home NPPV use in patients following a hospitalization for
AECOPD with acute hypercapnic respiratory failure on event-free survival after an index admis-
sion.
Methods: We conducted a retrospective, single-center, chart review on patients hospitalized
in 2011 with a diagnosis of AECOPD, hypercapnia, and used NPPV during hospitalization. 166
patients were included and were divided into two groups: patients who used NPPV post
discharge and patients who did not.
Results: Patients in the NPPV post discharge group demonstrated superior event-free survival
compared to the no-NPPV post discharge group (y2 Z 23.8, p < 0.0001). The NPPV post
discharge group had a statistically significant reduction in hospital readmissions (40% versus
75%, p < 0.0001) through 180 days from the index admission.bation of chronic obstructive pulmonary disease; AHRF, acute hypercapnic respiratory failure; COPD,
; EPAP, expiratory positive airway pressure; FVC, forced vital capacity; HRQoL, health-related quality
inspiratory positive airway pressure; NPPV, non-invasive positive pressure ventilation.
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Home non-invasive ventilation use following acute hypercapnic respiratory failure in COPD 723Conclusions: Patients who used NPPV following an admission for AECOPD with hypercapnic res-
piratory failure had lower readmission rates and improved event-free survival after 180 days
from an index admission compared to patients who did not use NPPV post discharge.
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Chronic obstructive pulmonary disease (COPD) continues to
be a leading cause of morbidity and death in the United
States and worldwide [1e3]. Hypercapnic respiratory fail-
ure is a phenomenon that may occur during acute exacer-
bations of COPD (AECOPD) and chronically as the disease
progresses [4]. Patients with COPD and hypercapnic respi-
ratory failure have a worse prognosis, are more likely to be
admitted to the hospital, and experience a faster deterio-
ration in their pulmonary and non-pulmonary function
[5,6,25]. Once hypercapnia develops, the two-year mor-
tality rate for COPD patients increases to 30e40% [7].
Non-invasive positive pressure ventilation (NPPV) has
been shown to be an effective treatment for acute hyper-
capnic respiratory failure (AHRF) during COPD hospitaliza-
tion. The use of NPPV in this setting reduces mortality,
decreases the need for endotracheal intubation, and re-
duces the duration of hospitalization [8e10,17,23,26]. Pa-
tients with altered levels of consciousness that is mild may
also tolerate NPPV during hospitalization for AECOPD [24].
The benefits, if any, from using home NPPV for chronic
hypercapnic respiratory failure is less clear. Improvements
in dyspnea scores and health-related quality of life (HRQoL)
measures have been established in stable severe COPD with
chronic hypercapnic respiratory failure [11e13,17,20]. In
stable severe COPD the long-term effects of NPPV on
spirometry and arterial blood gas measurements are con-
flicting [11e14,20]. Additionally, a mortality benefit or a
reduction in COPD exacerbations from the use of NPPV in
these patients has not been consistently demonstrated
[15e17,19].
The majority of studies that have assessed home NPPV
have evaluated severely obstructed but stable COPD pa-
tients with minimal hypercapnia. The benefits of home
NPPV during the period of clinical instability that immedi-
ately follows AECOPD hospitalization and acute hypercap-
nic respiratory failure have not been well studied. We
hypothesized that patients who used home NPPV immedi-
ately following an AECOPD admission with acute hyper-
capnic respiratory failure would have improved event-free
survival compared to patients who did not use NPPV post
discharge.Methods
Patients
We conducted a retrospective, single-center, chart review
in patients admitted for AECOPD with hypercapnic respi-
ratory failure who received bilevel NPPV during hospitali-
zation. A total of 1429 consecutive admissions with aprimary or secondary discharge diagnosis of AECOPD from
January 2011 to December 2011 were reviewed. All ad-
missions were from a single academic university hospital in
Philadelphia, Pennsylvania. Inclusion criteria were a pri-
mary or secondary discharge diagnosis of AECOPD (ICD-9
code 491.21), hypercapnic respiratory failure during hos-
pitalization (defined as PaCO2 > 45 mmHg on arterial blood
gas), and the use of bilevel NPPV during hospitalization.
Exclusion criteria were patients discharged to hospice,
patients who did not receive an arterial blood gas during
their hospital stay (no documented hypercapnia), and pa-
tients who did not receive NPPV during hospitalization. IRB
approval was obtained from the Office for Human Subjects
Protections Institutional Review Board of Temple University
(approval number: 20135).
Study design
Patients who qualified for the study were divided into two
groups: patients who used NPPV post discharge, and pa-
tients who did not use NPPV following discharge. The latter
group consisted of patients who were not prescribed NPPV
at the time of discharge and patients discharged with NPPV
who were determined to be noncompliant. Compliance
with bilevel NPPV was determined through review of both
the outpatient electronic medical record and documenta-
tion in subsequent readmissions. Data related to home
ventilator meter hours was not available and did not
contribute to the determination of compliance. In the case
of technical problems with the home ventilator, patients
were expected to contact their pulmonologist and durable
medical equipment provider to troubleshoot and resolve
such issues.
Data was collected pertaining to the index admission
that included patient comorbidities, endotracheal intuba-
tion, admission to the intensive care unit, length of hospital
stay, demographics, arterial blood gas values on admission
and at discharge, discharge medications, and IPAP and EPAP
settings for bilevel NPPV at discharge. For individual pa-
tients who had multiple admissions that met the eligibility
criteria for our study, the first admission chronologically
was considered the index admission. Pulmonary function
test and echocardiogram results were historical data ob-
tained from the electronic medical record.
Study outcomes
The primary outcome for our study was event-free survival.
This was defined as time after the index admission without
re-hospitalization or death. Secondary outcomes were
readmission rates, all-cause mortality rates, readmission
rates to the intensive care unit (ICU), and readmissions
requiring endotracheal intubation. Data for the secondary
724 J.A. Galli et al.outcomes were collected at 30, 90, and 180 days after the
index admission. Readmission data was obtained through an
electronic medical record that documented readmissions at
our institution. Mortality data was obtained through docu-
mented deaths during readmissions and from the social
security death index.
Analysis and statistics
The study results are expressed as a percentage or
mean  standard deviation. Statistical analysis was per-
formed using Fisher’s exact and Student’s t test. Kaplan
Meier analysis was performed for event-free survival. Cox
regression analysis was performed to assess the association
of NPPV use and event-free survival with other significant
variables. The two study groups were subsequently
matched using propensity scores derived from the variables
age, BMI, FEV1, OSA/OHS, Home O2, PaCO2 at discharge,
and admission date. Characteristics that differed after
propensity score matching were further adjusted for.
Results
Baseline characteristics and patient population
Of the 1429 admissions for AECOPD that were reviewed, 166
patients were included in the study (Fig. 1). The primary
reason for study exclusion was that they had not received
bilevel NPPV during hospitalization (1251 patients). In
addition, seven patients were excluded who were dis-
charged to hospice, while five patients were excluded for
not having documented hypercapnia. Of the 166 patients
who met inclusion criteria, 78 of these patients constituted
the NPPV post discharge group while 88 patients comprised
the no-NPPV post discharge group (Fig. 1).
The reason for not being prescribed NPPV at the time of
discharge varied within the no-NPPV post discharge group.
Physician discretion was the most common reason for not
being prescribed home NPPV and occurred in thirty-sixFigure 1 Flow diagram representing the study patient
population.patients. Twelve patients could not obtain insurance
approval for home NPPV, while sixteen patients declined
home NPPV during discharge planning of the index
admission.
There were several differences in the baseline charac-
teristics of the two study groups (Table 1). The mean age of
the NPPV post discharge group was 3.3 years younger than
the no-NPPV post discharge group (61.6 versus 64.9 years),
which was statistically significant (p Z 0.04). Overall,
women comprised 63% of the study population with more
women than men in both study groups. The NPPV post
discharge group had a greater proportion of patients with a
history of obstructive sleep apnea or obesity hypo-
ventilation syndrome than the no-NPPV post discharge
group (47.4% versus 26.1%), which was statistically signifi-
cant (p Z 0.006). Race distribution was similar in both
groups, with African American patients comprising 51% of
the study population.
Historical data for pulmonary function tests were avail-
able for 104 of the 166 study patients. The percent pre-
dicted forced vital capacity (FVC) was lower in the NPPV
post discharge group (59% versus 68.7%, pZ 0.01). No other
spirometry measurements were significantly different be-
tween the two groups. The majority of patients (157 of 166)
had an echocardiogram in the electronic medical record.
There was a similar prevalence of diastolic and systolic
heart failure in the respective groups. Previous cardiac
catheterization data was available for 59 of the 166 pa-
tients. This revealed a similar prevalence of coronary artery
disease and pulmonary hypertension in the two study
groups.
A higher proportion of index admissions involved ICU
stays in the no-NPPV post discharge group compared to the
NPPV post discharge group (71.6% versus 47.4%, pZ 0.002).
Discharge PaCO2 was also significantly lower in the no-NPPV
post discharge group than in the NPPV post discharge group
(55.2 mmHg versus 61.2 mmHg, p < 0.001). In the NPPV
post discharge group the mean IPAP setting at discharge
from the reference admission was 22.1  6.2 cm H2O while
the mean EPAP setting was 5.9  1.8 cm H2O.
Mortality and readmission rates
The NPPV post discharge group had a statistically significant
reduction in hospital readmissions at 30, 90, and 180 days
from the index admission (Table 2). At 180 days, 75% of
patients in the no-NPPV post discharge group had at least
one readmission, while only 39.7% of the patients in the
NPPV post discharge group did (p Z 0.002). There was a
trend towards reduced mortality in the NPPV post discharge
group in comparison to the no-NPPV post discharge group
(10% mortality versus 19% mortality at 180 days, pZ 0.13),
but these values did not reach statistical significance.
ICU readmissions and intubation rates
The NPPV post discharge group had a reduction in the rate
of readmissions requiring a stay in the intensive care unit.
This reduction reached statistical significance at 30, 90,
and 180 days of follow-up from the index admission (Table
2). The NPPV post discharge group also had a lower rate of
Table 1 Baseline characteristics & index admission data.
Baseline characteristic Used NPPV post
discharge (N Z 78)
No-NPPV post discharge
(N Z 88)
P value
Age (years) 61.6  10.2 64.9  10.8 0.04
Body mass index (kg/m2) 33.7  12.0 30.6  13.0 0.11
Current smoker e no. (%) 15 (19.2%) 24 (27.3%) 0.27
Race e no. (%)
Caucasian 30 (38.5%) 27 (30.7%) 0.33
Black 40 (51.3%) 45 (51.2%) 1.00
Hispanic 8 (10.2%) 15 (17.0%) 0.26
Other 0 (0%) 1 (1.1%) 1.00
Male sex e no. (%) 33 (42.3%) 29 (33.0%) 0.26
Past medical history e no. (%)
OSA/OHS 37 (47.4%) 23 (26.1%) 0.006
Pulmonary HTN 20 (25.6%) 21 (23.9%) 0.86
CHF (EF < 40%) 7 (9.0%) 11 (12.5%) 0.62
Diastolic dysfunction 37 (47.4%) 35 (49.8%) 0.43
CAD 19 (24.4%) 16 (18.2%) 0.35
CVA 3 (3.9%) 7 (8.0%) 0.34
DM 37 (47.4%) 30 (34.1%) 0.08
HTN 64 (82.1%) 73 (83.0%) 1.00
Lung cancer (active) 2 (2.6%) 5 (5.7%) 0.45
Other cancer (active) 1 (1.3%) 4 (4.6%) 0.37
Spirometry
FEV1 (% predicted) 34.5  16.3 (n Z 57) 40  16.3 (n Z 47) 0.09
FVC (% predicted) 59  19.8 (n Z 57) 68.7  18.9 (n Z 47) 0.01
FEV1/FVC ratio 0.47  0.2 (n Z 57) 0.47  0.2 (n Z 47) 0.90
RV (% predicted) 154.6  65.7 (n Z 43) 152.6  65.8 (n Z 34) 0.89
TLC (% predicted) 92.9  28.4 (n Z 43) 98.9  27.9 (n Z 34) 0.36
RV/TLC ratio 58.2  11.8 (n Z 43) 56.7  13.4 (n Z 34) 0.60
Index admission
ICU e no. (%) 37 (47.4%) 63 (71.6%) 0.002
Intubated e no. (%) 14 (18.0%) 21 (23.9%) 0.45
Length of stay (days) 9.9  8.5 9.5  7.5 0.77
pH on admission 7.30  0.08 7.27  0.1 0.03
PaCO2 on admission (mmHg) 74.6  17.8 76.8  23.4 0.49
pH at discharge 7.40  0.04 7.42  0.05 0.03
PaCO2 at discharge (mmHg) 61.2  11.2 55.2  11.4 <0.001
Discharge medications
Home O2 e no. (%) 64 (82.1%) 61 (69.3%) 0.07
Prednisone e no. (%) 61 (78.2%) 71 (80.7%) 0.70
Antibiotic e no. (%) 25 (32.1%) 25 (28.4%) 0.62
LABA e no. (%) 70 (89.7%) 76 (86.4%) 0.63
SABA e no. (%) 76 (97.4%) 88 (100%) 0.22
ICS e no. (%) 69 (88.5%) 76 (86.4%) 0.82
Data are presented as mean  SD unless otherwise specified.
OSA, obstructive sleep apnea; OHS, obesity hypoventilation syndrome; HTN, hypertension; CHF, congestive heart failure; CAD, coronary
artery disease; CVA, cerebrovascular accident; DM, diabetes mellitus; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity;
RV, residual volume; TLC, total lung capacity; ICU, intensive care unit; PaCO2, arterial carbon dioxide tension; LABA, long acting beta
agonist; SABA, short acting beta agonist; ICS, inhaled corticosteroid.
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reached statistical significance at 180 days of follow-up.
Event-free survival
We constructed a KaplaneMeier survival curve for event-
free survival as time measured from the index admission.
Patients in the NPPV post discharge group demonstratedsuperior event-free survival as compared to the no-NPPV
post discharge group (y2 Z 23.8, p < 0.0001) (Fig. 2).
Cox regression analysis and propensity scores for
event-free survival
A multivariate analysis was performed using a Cox regres-
sion model to identify baseline characteristics associated
Table 2 Results for secondary endpoints comparing NPPV post discharge versus no-NPPV post discharge.
Used NPPV post
discharge (N Z 78)
No-NPPV post
discharge (N Z 88)
P value
Number of patients with readmission e no (%)
At 30 days 12 (15%) 35 (40%) <0.001
At 90 days 20 (26%) 53 (60%) <0.0001
At 180 days 31 (40%) 66 (75%) <0.0001
Number of patients with readmission to ICU e no (%)
At 30 days 2 (3%) 12 (14%) 0.01
At 90 days 5 (6%) 20 (23%) 0.004
At 180 days 6 (8%) 28 (32%) 0.0001
Number of patients intubated at readmission e no (%)
At 30 days 1 (1%) 7 (8%) 0.07
At 90 days 4 (5%) 11 (13%) 0.11
At 180 days 5 (6%) 16 (18%) 0.03
Mortality e no (%)
At 30 days 3 (4%) 6 (7%) 0.5
At 90 days 6 (8%) 11 (13%) 0.44
At 180 days 8 (10%) 17 (19%) 0.13
NPPV, non-invasive positive pressure ventilation; ICU, intensive care unit.
726 J.A. Galli et al.with reduced event-free survival (Table 3). No-NPPV at
discharge, home O2 use, LABA use, and pulmonary HTN
were variables associated with reduced event-free survival.
The two study groups were subsequently matched with the
use of propensity scores. Propensity scores for group
matching were calculated using the variables of age, BMI,
FEV1, OSA/OHS, PaCO2 at discharge, home O2, and admis-
sion date. The matching process resulted in 77 patients
from the NPPV post discharge group being statistically
matched with 77 patients from the no-NPPV post discharge
group. After matching with propensity scores the charac-
teristics OSA/OHS and PaCO2 at discharge still differed
between groups. These two variables were further adjusted
for between the matched groups (Table 3). Subjects who
did not use NPPV post discharge had inferior event-free
survival through 180 days after statistical matching
compared to patients who used NPPV post discharge (HR
3.29, 95% CI 2.05e5.27, p < 0.0001) (Table 3).Figure 2 Kaplan Meier curve of event-free survival
comparing patients who used NPPV post discharge versus pa-
tients who did not use NPPV post discharge.Discussion
Our retrospective study demonstrated that patients who
used home NPPV following hospitalization for AECOPD with
acute hypercapnic respiratory failure had improved event-
free survival and reduced readmission rates through six
months compared to patients who did not use NPPV post
discharge. Patients who used NPPV post discharge also had
lower readmission rates at six months, and a reduction in
readmissions requiring admission to the intensive care unit.
In a randomized controlled trial, Cheung and others
demonstrated that continued home NPPV use following an
AECOPD with acute hypercapnic respiratory failure (AHRF)
reduced the recurrence of severe AECOPD with AHRF
(requiring intermittent NPPV, intubation, or resulting in
death) at one year compared to a control group using home
CPAP [27]. While our study looked at different primary and
secondary endpoints, our findings of reduced need for
endotracheal intubations and reduction in readmissions to
the intensive care unit through 180 days indirectly corrob-
orates Cheung and others findings that continued home
NPPV reduces recurrent severe AECOPD. Also in agreement
with our study, Cheung and colleagues did not demonstrate
a reduction in death from the continued use of NPPV.
One limitation of our study is that readmission data was
only collected from our home institution’s health care
system. Consequently, this inevitably resulted in a lower
reported readmission rate for both study groups. While
unlikely, it cannot be excluded that this may have skewed
the readmission rates in favor of the NPPV post discharge
group. Another limitation is the possibility of noncompli-
ance as a confounding factor in the no-NPPV post discharge
group. Twenty-four of the eighty-eight patients (27.3%) in
the no-NPPV post discharge group consisted of patients who
were documented to be noncompliant with home NPPV.
The possibility that these patients were also noncompliant
with other home medications for COPD cannot be excluded
and this could have contributed to their poorer outcomes.
Table 3 Association of NPPV and event-free survival with propensity score matching and Cox regression analysis.a
Variable Univariate Multivariateb
HR (95% CI) P value HR (95% CI) P value
NPPV (no versus yes) 3.11 (1.99e4.87) <0.0001 3.29 (2.05e5.27) <0.0001
Home O2 1.93 (1.10e3.39) 0.02 1.94 (1.10e3.41) 0.02
LABA 2.57 (1.16e5.66) 0.02 2.62 (1.16e5.92) 0.02
Pulmonary HTN 1.74 (1.09e2.76) 0.02 1.77 (1.11e2.84) 0.02
CI, Confidence interval; HR, Hazard ratio; NPPV, Non-invasive positive pressure ventilation; LABA, long acting beta agonist; HTN,
hypertension.
a Propensity scores for matching were calculated using age, BMI, FEV1, OSA/OHS, PaCO2 at discharge, Home O2, and admission date.
b Matched groups further adjusted for variables OSA/OHS and PaCO2 at discharge (After matching with propensity scores the char-
acteristics OSA/OHS and PaCO2 at discharge still differed between groups, thus necessitating further adjusting).
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this study there is a possibility for disequilibrium between
the study groups not captured by the variables studied.
Patients who require the use of bilevel NPPV during a
hospitalization for AECOPD with acute hypercapnic respi-
ratory failure have a high risk for significant morbidity and
mortality in the interim [5,22]. In a study by Chu and col-
leagues, patients who were treated with NPPV for AECOPD
with acute hypercapnic respiratory failure had a 79.9%
readmission rate and a 49.1% mortality rate at one year [5].
The results from our study are promising and demonstrate
that home NPPV may reduce readmission rates and improve
event-free survival following hospitalization. Future pro-
spective randomized and controlled trials are needed to
evaluate the use of home NPPV in patients immediately
following an admission for AECOPD with acute hypercapnic
respiratory failure to substantiate the results from our
retrospective study.
In conclusion, our retrospective study has demon-
strated that following an admission for AECOPD with
acute hypercapnic respiratory failure patients who used
bilevel NPPV post discharge at home on a daily basis had
lower readmission rates, reduced readmissions requiring a
stay in the intensive care unit, and improved event-free
survival. Patients are at a high risk for hospital read-
missions and mortality following an admission for AECOPD
with hypercapnic respiratory failure, and continued home
use of nocturnal NPPV after discharge may be a consid-
eration for treatment in this population. Prospective,
randomized and controlled studies are needed to
corroborate our results reported from this retrospective
analysis.
Conflict of interests/Acknowledgments
Author contributions: Dr. Galli contributed to study
concept and design, data collection, analysis and inter-
pretation of data, and drafting and revision of the manu-
script. Dr. Krahnke contributed to study concept and
design, analysis and interpretation of data, and revision of
the manuscript. Dr. Criner served as the guarantor of the
paper, contributed to study concept and design, analysis
and interpretation of the data, critical revision of the
manuscript for important intellectual content, and
approval of the final manuscript.Dr. Mamary and Dr. Shenoy contributed to study concept
and design, and analysis and interpretation of the data. Dr.
Zhao performed statistical analysis and interpretation of
data.
Financial/nonfinancial disclosures: Dr. Criner has
served on Advisory Committees for Dey, Boehringer Ingel-
heim, Ikaria, Uptake Medical, PortAero and Pulmonx, Inc.
Dr. Criner has received research grants from: Boehringer
Ingelheim, Forest, Actelion, GlaxoSmithKline, Advanta,
Daiichi Asubio, Pfizer, Roche and Novartis Pharmaceuticals,
Emphasys Medical, Inc., and Aeris Therapeutics. All
research grant monies are deposited and controlled by
Temple University. Dr. Galli, Dr. Krahnke, Dr. Mamary, Dr.
Zhao, and Dr. Shenoy have no disclosures to report.
Role of sponsors: The content of this publication is
solely the responsibility of the authors.References
[1] Minin˜o AM, Xu JQ, Kochanek KD. Deaths: preliminary data for
2008. Natl Vital Stat Rep 2010;59(2). Hyattsville, MD: National
Center for Health Statistics.
[2] Mannino DM, Buist AS. Global burden of COPD: risk factors,
prevalence, and future trends. Lancet 2007;370:765e73.
[3] Anto JM, Vermiere P, Vestbo J, Sunyer J. Epidemiology of
chronic obstructive pulmonary disease. Eur Respir J 2001;17:
982e94.
[4] Budweiser S, Jorres RA, Pfeifer M. Treatment of respiratory
failure in COPD. Int J Chron Obstruct Pulmon Dis 2008;3:
605e18.
[5] Chu CM, Chan VL, Lin AW, et al. Readmission rates and life
threatening events in COPD survivors treated with non-
invasive ventilation for acute hypercapnic respiratory fail-
ure. Thorax 2004;59:1020e5.
[6] Ai-Ping C, Lee KH, Lim TK. In-hospital and 5-year mortality of
patients treated in the ICU for acute exacerbation of COPD: a
retrospective study. Chest 2005;128:518e24.
[7] Foucher P, Baudouin N, Merati M, et al. Relative survival
analysis of 252 patients with COPD receiving long-term oxygen
therapy. Chest 1998;113:1580e7.
[8] Ram FS, Picot J, Lightowler J, et al. Non-invasive positive
pressure ventilation for treatment of respiratory failure due
to exacerbations of chronic obstructive pulmonary disease.
Cochrane Database Syst Rev 2004;3:CD004104.
[9] British Thoracic Society Standards of Care Committee. Non-
invasive ventilation in acute respiratory failure. Thorax 2002;
57:192e211.
728 J.A. Galli et al.[10] Meduri GU. Noninvasive positive pressure ventilation in pa-
tients with acute respiratory failure. Clin Chest Med 1996;17:
513e53.
[11] Clini E, Sturani C, Rossi A, et al. The Italian multicentre study
on noninvasive ventilation in chronic obstructive pulmonary
disease patients. Eur Respir J 2002;20:529e38.
[12] Tsolaki V, Pastaka C, Karetsi E, et al. One-year non-invasive
ventilation in chronic hypercapnic COPD: effect on quality
of life. Respir Med 2008;102:904e11.
[13] Duiverman ML, Wempe JB, Bladder G, et al. Nocturnal non-
invasive ventilation in addition to rehabilitation in hypercap-
nic patients with COPD. Thorax 2008;63:1052e7.
[14] Casanova C, Celli BR, Tost L, et al. Long-term controlled trial
of nocturnal nasal positive pressure ventilation in patients
with severe COPD. Chest 2000;118:1582e90.
[15] McEvoy RD, Pierce RJ, Hillman D, et al. Nocturnal non-invasive
nasal ventilation in stable hypercapnic COPD: a randomised
controlled trial. Thorax 2009;64:561e6.
[16] Jones SE, Packham S, Hebden M, et al. Domiciliary nocturnal
intermittent positive pressure ventilation in patients with
respiratory failure due to severe COPD: long-term follow up
and effect on survival. Thorax 1998;53:495e8.
[17] Duiverman ML, Wempe JB, Bladder G, et al. Two-year home-
based nocturnal noninvasive ventilation added to rehabilita-
tion in chronic obstructive pulmonary disease patients: a
randomized controlled trial. Respir Res 2011;12:112.[19] Windisch W, Haenel M, Storre JH, et al. High-intensity non-
invasive positive pressure ventilation for stable hypercapnic
COPD. Int J Med Sci 2009;6:72e6.
[20] Perrin C, El Far Y, Vandenbos F. Domiciliary nasal intermittent
positive pressure ventilation in severe COPD: effects on lung
function and quality of life. Eur Respir J 1997;10:2835e9.
[22] Vitacca M, Clini E, Rubini F, et al. Non-invasive mechanical
ventilation in severe chronic obstructive lung disease and
acute respiratory failure: short- and long-term prognosis.
Intensive Care Med 1996;22:94e100.
[23] Nava S, Grassi M, Fanfulla F, et al. Non-invasive ventilation in
elderly patients with acute hypercapnic respiratory failure: a
randomised controlled trial. Age Ageing 2011;40:444e50.
[24] Scala R, Naldi M, Nava S, et al. Noninvasive positive pressure
ventilation in patients with acute exacerbations of COPD and
varying levels of consciousness. Chest 2005;128:1657e66.
[25] Vitacca M, Bianchi L, Ambrosino N, et al. Effects of acute on
chronic respiratory failure on hypercapnia and 3-month sur-
vival. Chest 2005;128:1209e15.
[26] Ambrosino N, Vagheggini G. Non-invasive ventilation in exacer-
bations of COPD. Int J Chron Obstruct Pulmon Dis 2007;2:471e6.
[27] Cheung A, Chan V, Liong J, et al. A pilot trial of non-invasive
home ventilation after acidotic respiratory failure in chronic
obstructive pulmonary disease. Int J Tuberc Lung Dis 2010;14:
642e9.
